D. E. Shaw & Co. Inc. Sells 336,949 Shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)

D. E. Shaw & Co. Inc. trimmed its position in shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX - Free Report) by 46.5% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 387,733 shares of the company's stock after selling 336,949 shares during the period. D. E. Shaw & Co. Inc. owned approximately 0.52% of SpringWorks Therapeutics worth $14,009,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Huntington National Bank raised its holdings in SpringWorks Therapeutics by 38.2% in the 4th quarter. Huntington National Bank now owns 694 shares of the company's stock valued at $25,000 after buying an additional 192 shares during the last quarter. AlphaQuest LLC lifted its position in shares of SpringWorks Therapeutics by 70.2% in the 4th quarter. AlphaQuest LLC now owns 1,004 shares of the company's stock worth $36,000 after purchasing an additional 414 shares during the period. Barclays PLC increased its holdings in SpringWorks Therapeutics by 0.3% in the fourth quarter. Barclays PLC now owns 156,123 shares of the company's stock worth $5,641,000 after purchasing an additional 447 shares in the last quarter. Virtus ETF Advisers LLC grew its stake in SpringWorks Therapeutics by 7.4% in the fourth quarter. Virtus ETF Advisers LLC now owns 9,037 shares of the company's stock valued at $327,000 after acquiring an additional 622 shares during the period. Finally, KBC Group NV raised its holdings in SpringWorks Therapeutics by 59.1% during the fourth quarter. KBC Group NV now owns 2,634 shares of the company's stock worth $95,000 after buying an additional 978 shares during the last quarter.

Insider Activity at SpringWorks Therapeutics

In other news, insider Bhavesh Ashar sold 1,016 shares of the business's stock in a transaction dated Thursday, February 20th. The shares were sold at an average price of $61.19, for a total transaction of $62,169.04. Following the transaction, the insider now owns 62,053 shares of the company's stock, valued at approximately $3,797,023.07. The trade was a 1.61% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Daniel Lynch sold 47,600 shares of the firm's stock in a transaction dated Thursday, February 20th. The stock was sold at an average price of $60.22, for a total value of $2,866,472.00. Following the sale, the director now directly owns 82,944 shares in the company, valued at $4,994,887.68. This trade represents a 36.46% decrease in their position. The disclosure for this sale can be found here. Insiders sold 146,944 shares of company stock worth $8,439,479 in the last 90 days. 7.83% of the stock is owned by corporate insiders.

SpringWorks Therapeutics Trading Up 0.2%

NASDAQ SWTX traded up $0.08 on Monday, reaching $46.19. 1,102,840 shares of the stock were exchanged, compared to its average volume of 2,101,969. The company's 50-day simple moving average is $43.95 and its two-hundred day simple moving average is $42.32. The firm has a market capitalization of $3.48 billion, a PE ratio of -13.28 and a beta of 0.77. SpringWorks Therapeutics, Inc. has a one year low of $28.21 and a one year high of $62.00.

SpringWorks Therapeutics (NASDAQ:SWTX - Get Free Report) last announced its quarterly earnings results on Friday, May 9th. The company reported ($1.11) EPS for the quarter, missing analysts' consensus estimates of ($0.81) by ($0.30). SpringWorks Therapeutics had a negative net margin of 134.73% and a negative return on equity of 46.74%. The firm had revenue of $49.09 million for the quarter, compared to the consensus estimate of $64.19 million. Sell-side analysts forecast that SpringWorks Therapeutics, Inc. will post -2.05 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on SWTX. HC Wainwright reaffirmed a "neutral" rating and set a $47.00 price objective (down from $74.00) on shares of SpringWorks Therapeutics in a report on Wednesday, April 30th. Guggenheim reaffirmed a "neutral" rating and set a $47.00 target price on shares of SpringWorks Therapeutics in a report on Monday, May 12th. Evercore ISI lowered SpringWorks Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Monday, April 28th. Wedbush reiterated a "neutral" rating and set a $47.00 price objective (down from $81.00) on shares of SpringWorks Therapeutics in a research report on Monday, April 28th. Finally, TD Cowen reaffirmed a "hold" rating and issued a $47.00 price objective (down previously from $66.00) on shares of SpringWorks Therapeutics in a research note on Tuesday, April 29th. Seven equities research analysts have rated the stock with a hold rating and one has given a buy rating to the stock. According to MarketBeat.com, SpringWorks Therapeutics currently has a consensus rating of "Hold" and an average target price of $52.57.

About SpringWorks Therapeutics

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.